Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

被引：0
|
作者：
Rummelt, C. [1 ]
Gorantla, S. P. [1 ]
Endres, C. [1 ,2 ]
Doehner, K. [3 ]
Meggendorfer, M. [4 ]
Heidel, F. [5 ]
Fischer, T. [6 ]
Haferlach, T. [4 ]
Duyster, J. [1 ,2 ,7 ]
von Bubnoff, N. [1 ,2 ,7 ,8 ]
机构：
[1] Uniklin Freiburg, Hamatol Onkol & Stammzelltransplantat, Innere Med 1, Freiburg, Germany
[2] DKFZ Heidelberg, Heidelberg, Germany
[3] Uniklin Ulm, Klin Innere Med 3, Ulm, Germany
[4] MLL, Munchner Leukamielabor, Munich, Germany
[5] Univ Klin Jena, Abt Hamatol & Med Onkol, Jena, Germany
[6] Otto von Guericke Univ, Med Ctr, Abt Hamatol & Onkol, Magdeburg, Germany
[7] DKTK, Freiburg, Germany
[8] UKSH Campus Lubeck, Klin Hamatol & Onkol, Lubeck, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V655
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [21] CCL5 mediates Target-Kinase independent resistance to FLT3 Inhibitors in FLT3-ITD-positive AML
    Waldeck, S.
    Rassner, M.
    Keye, P.
    Duyster, J.
    von Bubnoff, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 19 - +
  • [22] Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
    Qiu, Shaowei
    Paterson, Andrew J.
    Abraham, Ajay
    He, Jianbo
    Shah, Mansi
    Agarwal, Puneet
    Mullen, Amanda K.
    Li, Hui
    Harris, Mason W.
    Anderson, Nicholas R.
    Bhatia, Ravi
    BLOOD, 2018, 132
  • [23] Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jiang-kang
    Wison, Kelli
    Choi, Kwangmin
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2016, 128 (22)
  • [24] Synergy of FLT3 inhibitors and a small molecule inhibitor of LIM kinase1/2 in FLT3-ITD positive acute myeloblastic leukemia (AML)
    Braun, Thorsten
    Berrou, Jeannig
    Djamai, Hanane
    Dupont, Melanie
    Kaci, Anna
    Ehlert, Jan Erik
    Weber, Holger
    Baruchel, Andre
    Paublant, Fabrice
    Prudent, Renaud
    Gardin, Claude
    Dombret, Nerve
    CANCER RESEARCH, 2019, 79 (13)
  • [25] CCL5 mediates Target-Kinase independent resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD-positive AML
    Waldeck, S.
    Rassner, M.
    Philipp, U.
    Andrieux, G.
    Keye, P.
    Waterhouse, M.
    Duyster, J.
    von Bubnoff, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 143 - 143
  • [26] Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo
    Moore, Andrew S.
    Faisal, Amir
    Bavetsias, Vassilios
    Sun, Chongbo
    Atrash, Butrus
    Valenti, Melanie
    Brandon, Alexis de Haven
    Avery, Sian
    Raynaud, Florence I.
    Workman, Paul
    Pearson, Andrew D. J.
    Blagg, Julian
    Eccles, Suzanne A.
    Linardopoulos, Spiros
    BLOOD, 2010, 116 (21) : 1347 - 1348
  • [27] Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation
    Edwards, David K.
    Javidi-Sharifi, Nathalie
    Rofelty, Angela
    Rosenfeld, Claire
    Roth-Carter, Riley
    Tardi, Paul
    Mayer, Lawrence
    Tyner, Jeffrey W.
    BLOOD, 2016, 128 (22)
  • [28] Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
    Bazarbachi, Abdul Hamid
    Al Hamed, Rama
    Malard, Florent
    Mohty, Mohamad
    Bazarbachi, Ali
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [29] RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
    Cucchi, David G. J.
    Denys, Barbara
    Kaspers, Gertjan J. L.
    Janssen, Jeroen J. W. M.
    Ossenkoppele, Gert J.
    de Haas, Valerie
    Zwaan, C. Michel
    van den Heuvel-Eibrink, Marry M.
    Philippe, Jan
    Csikos, Tamas
    Kwidama, Zinia
    de Moerloose, Barbara
    de Bont, Eveline S. J. M.
    Lissenberg-Witte, Birgit I.
    Zweegman, Sonja
    Verwer, Femke
    Vandepoele, Karl
    Schuurhuis, Gerrit Jan
    Sonneveld, Edwin
    Cloos, Jacqueline
    BLOOD, 2018, 131 (22) : 2485 - 2489
  • [30] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
    Dan Xu
    Yishan Chen
    Ying Yang
    Zhao Yin
    Changfen Huang
    Qiang Wang
    Ling Jiang
    Xuejie Jiang
    Changxin Yin
    Qifa Liu
    Guopan Yu
    Journal of Translational Medicine, 20
12345